Delaying approval of a critical drug: Safety, efficacy, economics, compassion
- 1 December 1994
- journal article
- Published by Springer Science and Business Media LLC in Journal of Medical Humanities
- Vol. 15 (4), 243-250
- https://doi.org/10.1007/bf02273711
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Monoclonal Antibodies to Endotoxin New Allies Against Sepsis?Published by American Medical Association (AMA) ,1991
- A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative SepsisJAMA, 1991
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991
- Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndromeCritical Care Medicine, 1990
- Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patientsAntimicrobial Agents and Chemotherapy, 1988
- Effect of High-Dose Glucocorticoid Therapy on Mortality in Patients with Clinical Signs of Systemic SepsisNew England Journal of Medicine, 1987
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coliNew England Journal of Medicine, 1982
- Type-Specific and Cross-Reactive Antibodies in Gram-Negative BacteremiaNew England Journal of Medicine, 1972
- PROTECTION AGAINST LETHALITY OF E. COLI ENDOTOXIN WITH “O” ANTISERUM*Annals of the New York Academy of Sciences, 1966